{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670320044823040.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s00296-009-1303-y"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00296-009-1303-y.pdf"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/article/10.1007/s00296-009-1303-y/fulltext.html"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s00296-009-1303-y"}},{"identifier":{"@type":"PMID","@value":"20024554"}}],"dc:title":[{"@value":"Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis"}],"description":[{"notation":[{"@value":"We investigated the effects of anti-IL-6 receptor antibody, tocilizumab (TCZ), on lipid metabolism. Nineteen patients with rheumatoid arthritis (RA), entered in clinical case-control study of SAMURAI trial at Sasebo Chuo Hospital, were examined. Nine patients received TCZ monotherapy at 8 mg/kg intravenously every 4 weeks (TCZ group) and 10 patients received conventional DMARDs (control group). Serum total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), apolipoprotein (Apo) A-1, Apo A-2 and Apo B as well as disease activity score (DAS), C-reactive protein and serum amyloid A protein were examined at baseline and after 3 months of the treatment. IL-6 inversely was correlated with LDL, Apo A-1 and Apo A-2, and also tended to correlate with Apo B. In TCZ group, serum levels of TC, HDL, LDL, Apo A-1 and Apo A-2 were significantly increased after 3 months treatment with TCZ. There was no significant change in Apo B, the atherogenic index, and TC/HDL by the TCZ treatment. Changes in the DAS28-ESR negatively correlated with those in TC. In one patient, whose serum level of TCZ was not detected after 3 months of the treatment, the absence of the increment in serum levels of Apo A-1 and A-2 in the patient was remarkable. All of the markers did not change during 3 months in control group. These data may raise an important issue to evaluate the impact of these alternations in lipid metabolism for longer periods in RA patients treated with TCZ."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670320044823051","@type":"Researcher","foaf:name":[{"@value":"Shin-ya Kawashiri"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320044823045","@type":"Researcher","foaf:name":[{"@value":"Atsushi Kawakami"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320044823048","@type":"Researcher","foaf:name":[{"@value":"Satoshi Yamasaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320044823040","@type":"Researcher","foaf:name":[{"@value":"Takahiro Imazato"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320044823046","@type":"Researcher","foaf:name":[{"@value":"Naoki Iwamoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320044823044","@type":"Researcher","foaf:name":[{"@value":"Keita Fujikawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320044823041","@type":"Researcher","foaf:name":[{"@value":"Toshiyuki Aramaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320044823047","@type":"Researcher","foaf:name":[{"@value":"Mami Tamai"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320044823043","@type":"Researcher","foaf:name":[{"@value":"Hideki Nakamura"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320044823050","@type":"Researcher","foaf:name":[{"@value":"Hiroaki Ida"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320044823042","@type":"Researcher","foaf:name":[{"@value":"Tomoki Origuchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320044823049","@type":"Researcher","foaf:name":[{"@value":"Yukitaka Ueki"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320044823052","@type":"Researcher","foaf:name":[{"@value":"Katsumi Eguchi"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"01728172"},{"@type":"EISSN","@value":"1437160X"}],"prism:publicationName":[{"@value":"Rheumatology International"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2009-12-19","prism:volume":"31","prism:number":"4","prism:startingPage":"451","prism:endingPage":"456"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://link.springer.com/content/pdf/10.1007/s00296-009-1303-y.pdf"},{"@id":"http://link.springer.com/article/10.1007/s00296-009-1303-y/fulltext.html"},{"@id":"http://link.springer.com/content/pdf/10.1007/s00296-009-1303-y"}],"createdAt":"2009-12-18","modifiedAt":"2019-05-28","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Antibodies,%20Monoclonal","dc:title":"Antibodies, Monoclonal"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Antibodies,%20Monoclonal,%20Humanized","dc:title":"Antibodies, Monoclonal, Humanized"},{"@id":"https://cir.nii.ac.jp/all?q=Lipids","dc:title":"Lipids"},{"@id":"https://cir.nii.ac.jp/all?q=Receptors,%20Interleukin-6","dc:title":"Receptors, Interleukin-6"},{"@id":"https://cir.nii.ac.jp/all?q=Arthritis,%20Rheumatoid","dc:title":"Arthritis, Rheumatoid"},{"@id":"https://cir.nii.ac.jp/all?q=C-Reactive%20Protein","dc:title":"C-Reactive Protein"},{"@id":"https://cir.nii.ac.jp/all?q=Case-Control%20Studies","dc:title":"Case-Control Studies"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Randomized%20Controlled%20Trials%20as%20Topic","dc:title":"Randomized Controlled Trials as Topic"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004236344769536","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum Proteome Analysis in Patients with Rheumatoid Arthritis Receiving Therapy with Tocilizumab: An Anti-Interleukin-6 Receptor Antibody"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205108834944","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Modulation of Autoimmunity and Atherosclerosis　– Common Targets and Promising Translational Approaches Against Disease –"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s00296-009-1303-y"},{"@type":"OPENAIRE","@value":"doi_dedup___::0a5d2ab7c5166738233b7c1454f1c87e"},{"@type":"CROSSREF","@value":"10.1155/2013/607137_references_DOI_17X1MsCf8uTrxcdZiVLKNWNiM78"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-15-0167_references_DOI_17X1MsCf8uTrxcdZiVLKNWNiM78"}]}